Clinical trials: Virus Shedding
Upper Respiratory Tract Infections, Virus
Edinburgh and Lothian Virus Intervention Study in Kids
ELVIS Kids is a parallel, open label, randomised controlled trial (RCT) of Hypertonic Saline (HS) nose drops (~2.6% NaCl) vs. standard care in children <7 years of age with symptoms of an Upper Respiratory Tract Infection (URTI).
- Conditions
- Upper Respiratory Tract Infections, Virus, Virus Shedding, Pediatric ALL
- Trial name
- ELVIS Kids (NCT03463694)
- Testing
- Na Cl solution
- Where
- United Kingdom
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Ebola Virus Disease
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
LA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with…
- Trial name
- EBOLAPED (NCT05130398)
- Testing
- rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens
- Where
- Gabon
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Rotavirus Infection, Vaccine Response Impaired
The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
Rotavirus is the leading cause of diarrhea in children worldwide. Oral rotavirus vaccines work remarkably well in high-income countries, but for unclear reasons they underperform in low-income countries.
- Conditions
- Rotavirus Infection, Vaccine Response Impaired, Vaccine Virus Shedding
- Trial name
- NCT02992197
- Testing
- Rotarix, dose 1, Rotarix, dose 2
- Where
- Bangladesh
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Vermont
HIV Infections, Helminthiasis
Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation
Identifying methods to slow disease progression in patients with HIV-1 infection remains a top priority in many regions of the world.
- Trial name
- NCT00130910
- Testing
- Albendazole
- Where
- Kenya
- Volunteers
- 234 people
- Sponsor
- University of Washington
Novel (H1N1) Influenza
Virus Shedding and Environmental Deposition of a Novel Influenza Virus
An influenza pandemic has recently been declared, involving the novel A(H1N1) 'swine flu' virus. This has spread to almost 100 countries worldwide in less than two months, causing widespread disease so far in Mexico, USA and…
- Trial name
- NCT01046734
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people
- Sponsor
- University of Nottingham
Bacterial Vaginosis
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.
- Trial name
- MASH (NCT00464542)
- Testing
- Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Zika Virus, Zika Virus Disease
Persistence of Zika Virus in Semen After Acute Infection
This is a prospective observational laboratory evaluation of the persistence rate of zika virus (ZIKV) infection in semen by real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), and assessment of ZIKV…
- Conditions
- Zika Virus, Zika Virus Disease, Virus Shedding, Transmission
- Trial name
- NCT02733796
- Where
- Belgium
- Volunteers
- 15 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Rotavirus Diarrhea, Vaccine Virus Shedding
Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh
Oral polio and rotavirus vaccines are significantly less effective in children living in the developing world. Tropical enteropathy, which is associated with intestinal inflammation, decreased absorption and increased…
- Conditions
- Rotavirus Diarrhea, Vaccine Virus Shedding, Tropical Enteropathy
- Trial name
- PROVIDE (NCT01375647)
- Testing
- IPV (inactivated polio vaccine), Rotarix
- Where
- Bangladesh
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- University of Vermont
HIV Infections, Ulcer
Episodic Acyclovir Therapy for Genital Ulcers
The purpose of this study is to determine if acyclovir episodic treatment has an effect in ulcer healing and if it should be added to the syndromic management of genital ulcer disease.
- Conditions
- HIV Infections, Ulcer, Herpes Simplex
- Trial name
- NCT00164424
- Testing
- Acyclovir
- Where
- 2 sites in South Africa
- Volunteers
- 613 people
- Sponsor
- Centers for Disease Control and Prevention
Parainfluenza Infection
DAS181 in Patients With Parainfluenza
Background: Parainfluenza is a virus that can cause infections in people. Most people infected with this virus have mild symptoms including fever, cough, red eyes, or runny nose (a common cold).
- Trial name
- NCT01441024
- Testing
- DAS181
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Herpes Simplex
HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons
Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical and epidemiologic evidence show the role of HSV in increasing HIV infectiousness.
- Conditions
- HIV Infections, Herpes Simplex, Sexually Transmitted Diseases
- Trial name
- NCT00465205
- Testing
- Valacyclovir
- Where
- Peru
- Volunteers
- 20 people
- Sponsor
- University of Washington
Genital Herpes
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.
- Trial name
- NCT01658826
- Testing
- AIC316, Valacyclovir
- Where
- 4 sites in United States
- Volunteers
- 91 people
- Sponsor
- AiCuris Anti-infective Cures AG
Influenza, Healthy
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the…
- Trial name
- FluMist (NCT03143101)
- Testing
- FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
- Where
- 12 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Human Immunodeficiency Virus, Virus Shedding
The Compartmental Biology of HIV in the Male Genital Tract
Male participants taking tenofovir-emtricitabine (TDF/FTC) will provide semen and blood samples which will be analyzed to better understand the pharmacology of antiretroviral therapy in the male genital tract.
- Trial name
- NCT02638493
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Upper Respiratory Tract Infections, Virus
Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19)
ELVIS COVID-19 is a pragmatic web-based Bayesian adaptive randomised controlled, parallel group trial of hypertonic saline nasal irrigation and gargling (HSNIG) compared to standard care in participants with clinically suspected…
- Conditions
- Upper Respiratory Tract Infections, Virus, COVID, Virus Shedding
- Trial name
- NCT04382131
- Testing
- NaCl Solution
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Edinburgh
Healthy
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children
The primary objective of this study is to describe the 28-day post-final dose safety and tolerability of three doses of MEDI-559 at 10^5 FFU when administered to healthy RSV seronegative children 1 to <24 months of age.
- Trial name
- MEDI-559 (NCT00767416)
- Testing
- MEDI-559
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy
A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age
The primary objective of this study is to describe the safety and tolerability of 3 doses of MEDI-560 at 10^5 TCID50 when administered to children 6 to < 12 months of age who are HPIV3 (human parainfluenza virus type 3)…
- Trial name
- NCT00508651
- Testing
- MEDI-560
- Where
- 23 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Avian Influenza
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths…
- Conditions
- Influenza, Avian Influenza, Severe Influenza
- Trial name
- NCT00298233
- Testing
- Oseltamivir
- Where
- 12 sites in Singapore, Thailand and 1 more
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Niclosamide for Mild to Moderate COVID-19
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04399356
- Testing
- Niclosamide, Telehealth monitoring
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Tufts Medical Center
Respiratory Infections, Acute, Respiratory Syncytial Virus
RSV Challenge in Healthy Adults
The purpose of this study is to measure the immune response (how the body fights infection) to an experimental preparation of live Respiratory Syncytial Virus (RSV).
- Trial name
- NCT00100373
- Testing
- RSV challenge material
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)